Summary of Recent Deal Activity
- PDF / 5,830,926 Bytes
- 12 Pages / 612.28 x 790.87 pts Page_size
- 37 Downloads / 185 Views
Summary of Recent Deal Activity Drug Discovery Technologies Companies
Type of Deal
Details
Abbott Laboratories, Celera Genomics
R&D agreement
Abbott Laboratories and Celera Genomics have formed a strategic collaboration to discover, develop and commercialize therapies for the treatment of cancer. The collaboration will encompass the development of therapeutic antibodies and smallmolecule drugs against over-expressed cell-surface proteins that have been associated with cancer and validated as therapeutic targets through proteomics research at Celera Genomics.
Affymetrix, Immusol
R&D agreement
Immusol has formed a strategic collaboration with Affymetrix that will facilitate the discovery and characterization of new as well as existing targets for cancer therapies. Immusol will utilize Affymetrix's GeneChip technology to identify distinct oncology pathways from its engineered tumor cells in biological assays. These modified cancer cells were developed at Immusol by specific down-regulation of tumor suppressors or oncogenes. Using GeneChip technology, expression of associated, affected genes will be analyzed and compared. The program aims to elucidate potential novel transformation pathways and to acquire and validate additional therapeutic target candidates. Moreover, targets will be examined over time and with varying perturbational events, allowing mechanistic information about a drug or drug target effect. Immusol will retain all rights for any discoveries.
Amgen, Dyax
Licensing agreement
Dyax has granted Amgen a nonexclusive license to its proprietary antibody phage display libraries for the discovery of human antibodies for therapeutic and diagnostic product development. Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, product license exercise fees, clinical milestone payments, and royalties on net sales of products that may result from Amgen's use of the Dyax libraries. The agreement provides Amgen with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.
AstraZeneca, Cell Signaling Technology
R&D agreement
Cell Signaling Technology {CSn has an agreement with AstraZeneca to perform a pilot study profiling select AstraZeneca compounds with CST s Global Phospho-Signature technology to discover novel, informative biomarkers of protein tyrosine kinase (PTKl target inhibition . Global Phospho-Signature (GPS) phospho-proteomics technology is a patent-pending methodology combining immunoaffinity purification and mass spectroscopy to determine cellular PTK phosphorylation profiles. Biomarkers discovered with GPS may enable the development of profiling assays to monitor targeted therapeutic pharmacodynamics and efficacy.
Aventis, Astex Technology
R&D agreement
Astex Technology has extended its existing structural biology research agreement with Aventis in the area of cytochrome P450s. Under the terms of the extension, Ave
Data Loading...
